Our production hub in L’Aquila hosts two manufacturing units. The first is dedicated to the production of medicines in the primary care sector, while the second focuses on the production of biotechnological active ingredients for the treatment of rare diseases.
The heart of Dompé lies in its production hub in L’Aquila, which spans over 1,8 Mln square feet. It is here that our vision comes to life: transforming scientific and technological discoveries into therapeutic solutions.
The facility includes two distinct production units.
The L’Aquila hub also houses warehouses, administrative offices, quality control laboratories, and other facilities such as research and development labs dedicated to identifying new therapies for rare diseases.
Since 1993, over €200 million has been invested in the L’Aquila site. Today, the hub boasts numerous dedicated facilities designed to enable Dompé to conduct cutting‑edge research and produce and distribute high‑quality medicines to the market.
Biotech production is characterized by tailored processes and cycles for each active ingredient, divided into two distinct phases: Upstream and Downstream.
The microorganisms are cultivated in bioreactors that maintain optimal conditions of temperature, acidity, and oxygenation to support the biological processes that lead to the synthesis of active ingredients. At the end of this phase, teams of biotechnologists and specialized technicians recover the cells to extract and purify the desired product.
The production of small molecules for primary care involves several process cycles: weighing, granulation and/or preparation, followed by primary and secondary packaging. Quality, efficiency, and flexibility are continuously monitored. Our pharmaceutical unit is also equipped with serialization and aggregation systems to ensure full traceability of the manufactured batches.
Our facility is equipped with cutting-edge systems and technologies, but such efficient production is only possible thanks to the expertise, successful management, and teamwork of our people. We firmly believe that every professional role adds value to our company. That’s why we foster a mindset focused on solution-seeking.
For example, by promoting collaboration across departments, we are able to respond quickly to market changes and find effective solutions. We consider this a key competitive advantage.
At our facility, we have successfully adopted a production approach based on lean manufacturing and just-in-time procurement, meaning we order raw materials in alignment with production schedules.
At our production site in L’Aquila, research into how to make manufacturing even more efficient is ongoing. Beyond simple data acquisition, it is real-time analysis that enables us to implement targeted and precise improvement actions.
The benefits of digital technologies extend far beyond production processes: our research laboratories, maintenance operations, training program management, and supply chain processes all gain significant advantages from investments in digitalization.
Our current production processes are already highly efficient, but digital technologies will drive further improvements in performance and productivity.
Since 2012, all investments have complied with Industry 4.0 standards, allowing us to expand the digitalization of the facility. From the outset, critical utilities have been equipped with SCADA systems for supervision and control, which are now undergoing modernization to address obsolescence and integrate new technologies.
Our Biotech facility is a center of excellence and the first site approved by the FDA for the production, packaging, quality control, release, and distribution of our drug cenegermin, based on recombinant human Nerve Growth Factor (rhNGF), for the treatment of neurotrophic keratitis.
